DERMAL DOSE Sample Clauses

DERMAL DOSE. Although dermal contact is not expected to represent a significant route of exposure, a simple calculation of potential dose may be performed for construction workers who could potentially contact contaminated groundwater during excavation or trenching activities. The amount of a chemical that a person may absorb due to dermal contact with contaminated environmental media depends on the following factors: o Chemical concentration in water, o Quantity of media in contact with skin, o Skin surface area contacted, o Frequency of exposure o Duration of exposure, and o Bioavailability of the chemical. The following equation identifies the relevant factors in the calculation of dose through the dermal route of exposure: Dermal Dose = Chemical x (10(-3) mg/ug) x (Area) x ET x DAR ------------------------------------------- WT Where: Dermal Dose = Dose received by dermal absorption of contaminants in water (mg/kg) [Water) = Concentration of chemical in water (ug/g, or ppm x 10(-6) 286 Area = Average exposed skin surface area (cm(2))[an average total body skin surface area is 17,535 cm(2) (Snydxx, xx al., 1975)] ET = Exposure time (minutes) DAR = Dermal absorption rate (ug/cm(2)-min) WT = Average human body weight (70 kg) Table 4-6 identifies the maximum detected concentrations of chemicals in shallow groundwater from the site (Levixx-Xxxxxx, 0089a, and McLaren 1989). Ideally, the potential dose from dermal contact with each of these compounds based on a typical concentration in the shallow ground water would be evaluated. However, the needed values relative to uptake rates and acceptable levels of exposure or cancer potency are available for only a few of the compounds. Therefore, an alternative is to examine representative compounds and infer the potential health impacts from exposure to multiple compounds. For the purposes of this assessment, ethylbenzene, a non-carcinogenic compound which was detected in the highest concentration of all the compounds present, and benzene, a carcinogenic chemical will be evaluated.
AutoNDA by SimpleDocs

Related to DERMAL DOSE

  • Supply of Product The JDC shall be responsible for determining the sources of, and arrangements for, the manufacture and supply of Products that the JDC believes will result in long-term profit maximization for such Products. The JDC shall endeavor to [ * ].

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Product The term “

  • Baxter and Nexell shall cooperate in any action taken by a third party solely involving a nullity action, opposition, reexamination or any other action taken by such third party alleging the invalidity or unenforceability of any Licensed Intellectual Property. Both parties agree to share equally in the cost of the defense of such Licensed Intellectual Property.

  • Combination Product The term “

  • Manufacturing License Subject to the terms of this Agreement, including without limitation Section 2.2, Theravance grants to GSK an exclusive license under the Theravance Patents and Theravance Know-How to make and have made API Compound or formulated Alliance Product in the Territory.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • API A. Reliant shall supply to Cardinal Health for Manufacturing and Packaging, at Reliant’s sole cost, the API and applicable reference standards in quantities sufficient to meet Reliant’s requirements for each Product as further set forth in Article 4. Prior to delivery of any of the API or reference standard to Cardinal Health for Manufacturing and Packaging, Reliant shall provide to Cardinal Health a copy of the API Material Safety Data Sheet (“MSDS”), as amended, and any subsequent revisions thereto. Reliant shall supply the API, reference standards, and Certificate of Analysis FOB the Facility no later than thirty (30) days before the scheduled Manufacture Date upon which such API will be used by Cardinal Health. Upon receipt of the API, Cardinal Health shall conduct identification testing of the API. Cardinal Health shall use the API solely and exclusively for Manufacturing and Packaging under this Agreement. The maximum volume of API that Reliant supplies to Cardinal Health shall not exceed the amount reflected in the Firm Commitment and the next six (6) months of the Rolling Forecast.

  • Licensed Territory Worldwide NIH Patent License Agreement—Exclusive APPENDIX C – ROYALTIES Royalties:

  • Manufacture (a) Manufacturer shall only manufacture the specific number of Products as requested by Company and at no time shall manufacture excess goods or overruns. Manufacturer shall not sell any Products bearing the Trademarks to any third parties without the express written consent of Company.

Time is Money Join Law Insider Premium to draft better contracts faster.